Monday, April 01, 2024 3:17:17 PM
Cash, cash equivalents, and investments of $134.5 million at December 31, 2023
GO4AWILDRIDE
STOCK MARKET SUCKS
Recent ANTX News
- AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights • Business Wire • 03/28/2024 08:10:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 10:11:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 12:01:31 PM
- AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease • Business Wire • 02/12/2024 11:45:00 AM
- AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference • Business Wire • 01/30/2024 09:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 11:19:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:03:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:08:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:59:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 11:06:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 11:05:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/02/2024 09:45:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/02/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 11:57:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:10:14 PM
- AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights • Business Wire • 11/09/2023 09:05:00 PM
- AN2 Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 11/06/2023 12:00:00 PM
- AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease • Business Wire • 10/18/2023 11:00:00 AM
- AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023 • Business Wire • 10/11/2023 04:01:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 11:21:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/02/2023 08:10:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:40:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/29/2023 08:11:11 PM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM